Ever since I was a young teen I knew I wanted to work on Wall Street. My motivations have certainly changed over time, as I have grown from being a securities trader to making deals that could positively affect people’s lives. I also have learned along with way that the best of intentions don’t always guarantee success or appreciation. Sometimes people’s lives are devastated by tragic circumstance or from a scenario of poor decisions built up over time. Either way, I have been on a journey these past few years to recover from my loss and to help those around me who also suffered from the financial collapse of 2008. My path has lead me here today.

I grew up in a typical American family with grandparents and plenty of relatives all around. It wasn’t until one day I really started to notice something different about my grandma who I didn’t get to see often but seemed to always be there. I never thought that a day would come when she wouldn’t be around. But that day did come and yet she was still alive. On that day I was startled when my grandmother didn’t recognize me. Over the succeeding weeks and months, I started to recognize that her thoughts and actions seemed strange. I started to feel as though I was losing my grandma, and over time, the dementia she was experiencing overcame her. I learned she had Alzheimer’s; the same disease that her parents and grandmother died from.

Over the past several years, I had an opportunity to enter the nutraceutical space. From that experience, I learned a lot about mental health, cognition, the remedies being researched and the challenges from a host of illnesses that adversely result in memory loss or worse. I did my research and found out how widespread and prevalent Alzheimer’s is in our modern society; it is a growing disease and growing faster than most.

I experienced first-hand on how difficult it is being a caretaker to someone afflicted with Alzheimer’s when my mother-in-law came to live with us.  At first, she was just forgetful, but over just a couple of years the disease progressed so quickly that she forgot how to swallow.  Doctors advised inserting a feeding tube which may have accelerated her decline.  The family decided not to do the surgery and within six months, she had passed away.  The experience was tough on our whole family.

It was at about this time my first inclination began to take shape; build a company that can raise the capital necessary to enable an alternative therapy or cure for Alzheimer’s to be commercialized and provide relief to millions of people. I was just learning about the effects of amyloidal plaque as a primary factor in the development of Alzheimer’s in patients. New theories were just surfacing on how to possibly reduce or eliminate the buildup of plaque and inhibit the growth of Alzheimer’s disease. With this new information I had a new research project.

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear in their mid-60s. Alzheimer’s disease is the most common cause of dementia among older adults.

Over the last couple of years someone very close to me has started to fall to the devastation of Alzheimer’s. My own father was diagnosed and even though he is on medication, he occasionally shows the classic symptoms. I feel helpless; he is my dad. You see Chuck is Milton C. Ault, Jr. for whom I am named after, the man who never once relented from being my father, ever. Once again this disease was hitting home. It was time to do something definitively before more people I love and care about are adversely affected.

The financial marketplace over the past few years had started to rebuild while the roads for new small cap companies became more treacherous with more stringent industry requirements and regulatory oversight. In 2012 with the passage of the JOBS Act, I saw an opportunity. For some in the marketplace, new hope began to spring up and the vehicle that was only a wish to me was passed into law.

A company I had founded and led for a time, Patient Safety Technologies, Inc., sold in the first quarter of 2014 for over $120,000,000. It was a great feeling knowing that I had the vision to recognize a medical opportunity that so many at the time saw no profit in and had no hope of it being accepted as an industry standard. All that and more was realized, and that inspired me to find a way to make a difference. I am not sure if it is fate or luck that was bestowed upon me simultaneously as new and old friends had started coming into my life. This enabled me to build a team of professionals. I began to have a vision of what was to be. With the support of my wife, we began to discuss the possibilities and the opportunities in research, to make a difference since the pharmaceutical leaders had yet to make a real breakthrough for Alzheimer’s. As a resolution for the new year 2016, we set a goal, and in February, Alzamend Neuro was formed.

Some have asked me why I founded Alzamend Neuro.  In sharing our story, we hope that people understand that we are searching for a cure; not just for our family, but for families all over the world.  Thank you for joining us and everyone at Alzamend Neuro as we move forward to accomplish our mission in finding a cure.  Through Alzamend Neuro, we have the ability to affect change and the ability to make a difference.

Milton “Todd” Ault, III.